Status:
COMPLETED
Italian Validation of the Beaumont Behavioural Inventory (BBI)
Lead Sponsor:
Istituti Clinici Scientifici Maugeri SpA
Collaborating Sponsors:
A.O.U. Città della Salute e della Scienza
Conditions:
Amyotrophic Lateral Sclerosis
Eligibility:
All Genders
Brief Summary
Up to 50% of patients affected with amyotrophic lateral sclerosis (ALS) can show behavioral dysfunctions within the spectrum of frontotemporal degenerations (FTD) - namely, apathy, disinhibition, loss...
Eligibility Criteria
Inclusion
- possible, probable or definite ALS according to El Escorial revised criteria
Exclusion
- Any other clinically significant cardiovascular, gastrointestinal, hepatic, renal, neurological or psychiatric disorder or any other major concurrent illness that in the opinion of the investigator could interfere with the interpretation of the study results
Key Trial Info
Start Date :
September 17 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2020
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT04440644
Start Date
September 17 2019
End Date
November 30 2020
Last Update
October 22 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ICS Maugeri
Milan, Italy, 20138